Ardele Mandiriri

Ardele Mandiriri

Auto-generated profile, based on publicly available information

Ardele Mandiriri

Newlands Clinic Harare Zimbabwe

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2022 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
KTKatayoun Taghavi
Katayoun Taghavi
AMArdele Mandiriri
Ardele Mandiriri
TSTinei Shamu
Tinei Shamu
EREliane Rohner
Eliane Rohner
LBLukas Bütikofer
Lukas Bütikofer
JBJulia Bohlius
Julia Bohlius
Countries with high HIV prevalence, predominantly in sub-Sahahran Africa, have the highest cervical cancer rates globally. HIV care cascades successfully facilitated the scale-up of antiretroviral therapy. A cascade approach could similarly succeed to scale-up cervical cancer screening, supporting WHO’s goal to eliminate cervical cancer. We defined a Cervical Cancer Screening Cascade for women living with HIV (WLHIV), evaluating the continuum of cervical cancer screening integrated into an HIV clinic in Zimbabwe. We included WLHIV aged ≥18 years enrolled at Newlands Clinic in Harare from June 2012–2017 and followed them until June 2018. We used a cascade approach to evaluate the full continuum of secondary prevention from screening to treatment of pre-cancer and follow-up. We report percentages, median time to reach cascade stages, and cumulative incidence at two years with 95% confidence intervals (CI). We used univariable Cox proportional hazard regressions to calculate cause-specific hazard ratios with 95% CIs for factors associated with completing the cascade stages. We included 1624 WLHIV in the study. The cumulative incidence of cervical screening was 85.4% (95% CI 83.5–87.1) at two years. Among the 396 WLHIV who received screen-positive tests in the study, the cumulative incidence of treatment after a positive screening test was 79.5% (95% CI 75.1–83.2) at two years. The cumulative incidence of testing negative at re-screening after treatment was 36.1% (95% CI 31.2–40.7) at two years. Using a cascade approach to evaluate the full continuum of cervical cancer screening, we found less-than 80% of WLHIV received treatment after screen-positive tests and less-than 40% were screen-negative at follow-up. Interventions to improve linkage to treatment for screen-positive WLHIV and studies to understand the clinical significance of screen-positive tests at follow-up among WLHIV are needed. These gaps in the continuum of care must be addressed in order to prevent cervical cancer.

2 April 2024 in Journal of the International AIDS Society
Verified
Journal Article
Open access
MPMarie Kerbie Plaisy
Marie Kerbie Plaisy
AMAlbert K. Minga
Albert K. Minga
GWGilles Wandeler
Gilles Wandeler
GMGad Murenzi
Gad Murenzi
NSNiharika Samala
Niharika Samala
TAthe Sentinel Research Network of the International epidemiology Databases to Evaluate AIDS
the Sentinel Research Network of the International epidemiology Databases to Evaluate AIDS
Introduction: Liver disease is a leading cause of morbidity and mortality among persons living with HIV (PLHIV). While chronic viral hepatitis has been extensively studied in low‐ and middle‐income countries (LMICs), there is limited information about the burden of metabolic disorders on liver disease in PLHIV.Methods: We conducted a cross‐sectional analysis of baseline data collected between October 2020 and July 2022 from the IeDEA‐Sentinel Research Network, a prospective cohort enrolling PLHIV ≥40 years on antiretroviral treatment (ART) for ≥6 months from eight clinics in Asia, Americas, and central, East, southern and West Africa. Clinical assessments, laboratory testing on fasting blood samples and liver stiffness measurement (LSM)/controlled attenuation parameter (CAP) by vibration‐controlled transient elastography were performed. Multivariable logistic regression models assessed factors associated with liver fibrosis (LSM ≥7.1 kPa) and steatosis (CAP ≥248 dB/m). Population attributable fraction (PAF) of each variable associated with significant liver fibrosis was estimated using Levin's formula.Results: Overall, 2120 PLHIV (56% female, median age 50 [interquartile range: 45−56] years) were included. The prevalence of obesity was 19%, 12% had type 2 diabetes mellitus (T2DM), 29% had hypertension and 53% had dyslipidaemia. The overall prevalence of liver fibrosis and steatosis was 7.6% (95% confidence interval [CI] 6.1−8.4) and 28.4% (95% CI 26.5−30.7), respectively, with regional variability. Male sex at birth (odds ratio [OR] 1.62, CI 1.10−2.40), overweight/obesity (OR = 2.50, 95% CI 1.69−3.75), T2DM (OR 2.26, 95% CI 1.46−3.47) and prolonged exposure to didanosine (OR 3.13, 95% CI 1.46−6.49) were associated with liver fibrosis. Overweight/obesity and T2DM accounted for 42% and 11% of the PAF for liver fibrosis, while HBsAg and anti‐HCV accounted for 3% and 1%, respectively. Factors associated with steatosis included overweight/obesity (OR 4.25, 95% CI 3.29−5.51), T2DM (OR 2.06, 95% CI 1.47−2.88), prolonged exposure to stavudine (OR 1.69, 95% CI 1.27−2.26) and dyslipidaemia (OR 1.68, 95% CI 1.31−2.16).Conclusions: Metabolic disorders were significant risk factors for liver disease among PLHIV in LMICs. Early recognition of metabolic disorders risk factors might be helpful to guide clinical and lifestyle interventions. Further prospective studies are needed to determine the causative natures of these findings.

5 November 2020 in Southern African Journal of HIV Medicine
Verified
Journal Article
Open access
PDF file
AMArdele M. Mandiriri
Ardele M. Mandiriri
MPMargaret J. Pascoe
Margaret J. Pascoe
TSTinei Shamu
Tinei Shamu
SLSara Lowe
Sara Lowe
The Southern African Journal of HIV Medicine is focused on HIV/AIDS treatment, prevention and related topics relevant to clinical and public health practice. The purpose of the journal is to disseminate original research results and support high-level learning related to HIV Medicine. It publishes original research articles, editorials, case reports/case series, reviews of state-of-the-art clinical practice and correspondence.

23 January 2019 in Southern African Journal of HIV Medicine
Verified
Journal Article
Open access
SLSara Lowe
Sara Lowe
TMTinashe Mudzviti
Tinashe Mudzviti
AMArdele Mandiriri
Ardele Mandiriri
TSTinei Shamu
Tinei Shamu
PMPetronella Mudhokwani
Petronella Mudhokwani
MPMargaret Pascoe
Margaret Pascoe
Background: Coinfection rates of HIV and sexually transmitted infections (STIs) are not widely reported in Zimbabwe and no local guidelines regarding the screening of STIs in people living with HIV exist.Objectives: This cross-sectional study was conducted to determine the prevalence and associated risk factors for STI coinfection in a cohort of HIV-infected women.Methods: Between January and June 2016, 385 HIV-infected women presenting for routine cervical cancer screening were tested for five STIs: Neisseria gonorrhoeae (NG), Chlamydia trachomatis(CT), Trichomonas vaginalis (TV), Herpes Simplex Virus (HSV) type 2 and Treponema pallidum (TP). Socio-demographic characteristics and sexual history were recorded. Multiple logistic regression was used to identify factors associated with the diagnosis of non-viral STIs.Results: Two hundred and thirty-three participants (60.5%) had a confirmed positive result for at least one STI: HSV 2 prevalence 52.5%, TV 8.1%, CT 2.1%, NG 1.8% and TP 11.4%. Eighty-seven per cent of the women were asymptomatic for any STI; 62.3% of women with a non-viral STI were asymptomatic. Women who had attended tertiary education were 90% less likely to have a non-viral STI (adjusted odds ratio [aOR]: 0.10, 95% confidence interval [CI]: 0.03–0.39, p < 0.01). Having more than three lifetime sexual partners was a significant predictor for a non-viral STI diagnosis (aOR: 3.3, 95% CI: 1.5–7.2, p < 0.01).Conclusion: A high prevalence of predominantly asymptomatic STIs is reported in a cohort of HIV-infected women. Syndromic management results in underdiagnosis of asymptomatic patients. More than three lifetime sexual partners and less formal education are risk factors for coinfection with non-viral STI. High-risk women should be screened using aetiological methods.

5 January 2024 in Southern African Journal of HIV Medicine
Verified
Journal Article
Open access
PDF file
TKTarisai Kufa
Tarisai Kufa
AMArdele Mandiriri
Ardele Mandiriri
TSTinei Shamu
Tinei Shamu
RMRacheal Shamiso Dube Mandishora
Racheal Shamiso Dube Mandishora
MPMargaret J. Pascoe
Margaret J. Pascoe
Background: Women living with HIV (WLWH) are six times more likely to develop cervical cancer (CC). There is also an increased incidence of CC in women with optimal HIV disease control, despite immune reconstitution due to antiretroviral therapy (ART). Objectives: This study describes the prevalence and age-specific genotype distribution of hrHPV among an urban cohort of WLWH. Additionally, we report the HIV disease profile and age-specific outcomes of hrHPV DNA screening in WLWH attending routine CC screening at Newlands Clinic, Harare, between January and December 2021. Method: This was a descriptive cross-sectional design based on a retrospective review of records of WLWH who were screened for hrHPV infection. We assessed the prevalence of hrHPV infection during the study period. Results: We included data for 2745 women who had an hrHPV DNA test. The median age at the time of testing was 45 years (interquartile range [IQR]; 37–52) The median duration on HIV ART was 10.2 years (IQR: 6.2–13.3). The proportion of women with undetectable viral loads (< 50 copies/mL) was 91.2%. The prevalence of hrHPV infection was 53%. The most prevalent genotypes were human papillomavirus (HPV) 58 (11%), HPV 52 (10%), HPV 35 (10%), and HPV 16 (9%). Conclusion: Our study reports a high prevalence of HPV and hrHPV including other subtypes than 16 and 18. These results highlight the continued importance of CC screening and prophylactic HPV vaccinations among WLWH.